Immune Deficiency
Conditions
Keywords
Fermented Maillard reacted whey protein, Natural killer cell activity, Immune function, Pre-albumin, Interleukin-12
Brief summary
To investigate the impact of supplementing fermented Maillard reacted whey protein (F-MRP) on natural killer (NK) cell activity, circulating cytokines and serum protein levels.
Detailed description
A randomized, double-blind, placebo-controlled study was conducted on 80 participant without diabetes and obesity. Over a 8-week testing period, the F-MRP group consumed 6 g of powder containing 4.2 g F-MRP each day, whereas the placebo group consumed the same amount with dextrin. NK cell activity (%) was measured based on the ratios of effector cells (E; peripheral blood mononuclear cells, PBMCs) from each participant to target cells (T; K562 cells) at E:T= 10:1, 5:1, 2.5:1, or 1.25:1.
Interventions
DIETARY_SUPPLEMENTFermented Maillard reacted whey protein (F-MRP)
6g of powder containing 4.2g fermented maillard reacted whey protein
DIETARY_SUPPLEMENTPlacebo
6g of maltodextrin
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Able to give informed consent * The levels of white blood cells within range 3x10\^3/μL\ 8x10\^3/μL * Males and females * 20-70 years old * Without no severe complications
Exclusion criteria
* Diabetes * White blood cell under 3x10\^3/μL or over 8x10\^3/μL * Pregnancy or breast-feeding * Hypersensitivity or disease history for milk protein * Liver disease, inflammation disease, or severe kidney failure disease * Cancer, lung disease, leukemia, or autoimmune disease * Psychological or neurological disease * Myocardiac infarction or cerebrovascular diseases within 6 months before screening * Consumption of other test products or drugs within 1 month before screening * Inflammation related disease within 1 month before screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Natural killer cell activity | At baseline |
| Change from baseline natural killer cell activity at 8-week | At baseline and 8-week follow-up |
Secondary
| Measure | Time frame |
|---|---|
| Interleukin-12 | At baseline |
| Change from baseline Interleukin-12 at 8-week | At baseline and 8-week follow-up |
| White blood cell | At baseline |
| Change from baseline Interferon-gamma at 8-week | At baseline and 8-week follow-up |
| Interferon-gamma | At baseline |
| Change from baseline white blood cell at 8-week | At baseline and 8-week follow-up |
Countries
South Korea
Outcome results
None listed